EUVIMEDEUVIMED entdecken
Crossref

Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study

Francisco Tsz Tsun Lai iD, Boyuan Wang, Cuiling Wei, Celine Sze Ling Chui iD, Xue Li, Ching Lung Cheung, Ian Chi Kei Wong iD, Esther Wai Yin Chan, Eric Yuk Fai Wan iD

Age and Ageing · 2024

DOI: 10.1093/ageing/afae180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Age and Ageing, 2024. Verfasst von Francisco Tsz Tsun Lai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Ko…. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19 Drug Treatment, Hospitalization, SARS-CoV-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Health and Medical Research Fund Research on COVID-19, Government of the Hong Kong Special Administrative Region, Research Grants Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Molnupiravir and nirmatrelvir-ritonavir are orally administered pharmacotherapies for mild to moderate COVID-19. However, the effectiveness of these drugs among very old (≥80 years), hospitalised patients remains unclear, limiting the risk–benefit assessment of these antivirals in this specific group. This study investigates the effectiveness of these antivirals in reducing mortality among this group of hospitalised patients with COVID-19.

Methods

Using a territory-wide public healthcare database in Hong Kong, a target trial emulation study was conducted with data from 13 642 eligible participants for the molnupiravir trial and 9553 for the nirmatrelvir-ritonavir trial. The primary outcome was all-cause mortality. Immortal time and confounding bias was minimised using cloning-censoring-weighting approach. Mortality odds ratios were estimated by pooled logistic regression after adjusting confounding biases by stabilised inverse probability weights.

Results

Both molnupiravir (HR: 0.895, 95% CI: 0.826–0.970) and nirmatrelvir-ritonavir (HR: 0.804, 95% CI: 0.678–0.955) demonstrated moderate mortality risk reduction among oldest-old hospitalised patients. No significant interaction was observed between oral antiviral treatment and vaccination status. The 28-day risk of mortality was lower in initiators than non-initiators for both molnupiravir (risk difference: −1.09%, 95% CI: −2.29, 0.11) and nirmatrelvir-ritonavir (risk difference: −1.71%, 95% CI: −3.30, −0.16) trials. The effectiveness of these medications was observed regardless of the patients’ prior vaccination status.

Conclusions

Molnupiravir and nirmatrelvir-ritonavir are moderately effective in reducing mortality risk among hospitalised oldest-old patients with COVID-19, regardless of their vaccination status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19 Drug TreatmentHospitalizationSARS-CoV-2HumansMaleFemaleAged, 80 and overHong KongAdministration, OralRitonavirCOVID-19HydroxylaminesTreatment OutcomeCytidineLeucine

Stichwörter der Autor:innen

SARS-CoV-2antiviral medicationscohort studyefficacygeriatricsmultimorbidityolder people

Substanzen

Antiviral AgentsmolnupiravirRitonavirHydroxylaminesCytidineLeucine

Autor:innen und Institutionen

  • Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Southern District, Hong Kong Special Administrati…
  • Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Southern District, Hong Kong Special Administrative Region, Chi…
  • Laboratory of Data Discovery for Health (D24H), 19 Science Park West Avenue, Hong Kong Science Park, Tai Po District, Hong Kong Special Administrative Region, China.
  • School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Southern District, Hong Kong Special Administrative Region, China.
  • School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Southern District, Hong Kong Special Administrative Region, China.
  • Advanced Data Analytics for Medical Science (ADAMS) Limited, 19 Science Park West Avenue, Hong Kong Science Park, Tai Po District, Hong Kong Special Administrative Region, China.

ORCID-Profile: Francisco Tsz Tsun Lai, Celine Sze Ling Chui, Ian Chi Kei Wong, Eric Yuk Fai Wan

Förderung

  • Health and Medical Research Fund Research on COVID-19
  • Government of the Hong Kong Special Administrative Region
  • Research Grants Council
  • Collaborative Research Fund
  • Health Bureau

Zitieren

APA

Lai, F. T. T., Wang, B., Wei, C., Chui, C. S. L., Li, X., Cheung, C. L., Wong, I. C. K., Chan, E. W. Y., & Wan, E. Y. F. (2024). Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study. Age and Ageing. https://doi.org/10.1093/ageing/afae180

Vancouver

Lai FTT, Wang B, Wei C, Chui CSL, Li X, Cheung CL, et al. Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study. Age and Ageing. 2024. doi:10.1093/ageing/afae180

BibTeX
@article{Lai2024,
  author = {Lai, Francisco Tsz Tsun and Wang, Boyuan and Wei, Cuiling and Chui, Celine Sze Ling and Li, Xue and Cheung, Ching Lung and Wong, Ian Chi Kei and Chan, Esther Wai Yin and Wan, Eric Yuk Fai},
  title = {Efficacy of COVID-19 Oral antivirals in hospitalised oldest-old with high morbidity burden: a target trial emulation study},
  journal = {Age and Ageing},
  year = {2024},
  doi = {10.1093/ageing/afae180}
}
Kostenlos starten →